Recent Advances in Type 1 Diabetes

Dear Colleagues,

We are pleased to announce a Special Issue of Endocrines focused on "Recent Advances in Type 1 Diabetes."

The prevalence of Type 1 Diabetes (T1D) is increasing worldwide, and it is crucial to shed light on the significant strides made in the diagnosis and management of this condition.

Since the discovery of insulin over a century ago, there have been remarkable advancements in multiple areas of T1D research and treatment. These include the following:

1. Early Identification of High-Risk Individuals: Research has led to the discovery of biomarkers for early identification of individuals at high risk of developing T1D during pre-clinical stages. This early detection is pivotal in implementing recently approved strategies to delay progression to the clinical stages of the disease.
2. Prolonging the Honeymoon Phase: ongoing studies aim to extend the honeymoon phase, when the body still produces some insulin, thus improving patient outcomes and quality of life.
3. Diabetes Technology: Technological advancements have revolutionized diabetes management. Automated insulin delivery systems, continuous glucose monitoring (CGM), and other innovative devices have become standard care, significantly improving glycemic control and reducing the burden of diabetes management.
4. Adjunct Therapies to Insulin: the introduction of adjunct therapies, alongside insulin, has enhanced the management of T1D, offering better glucose control and reducing complications.
5. Behavioral Research and Quality of Life: Significant attention is being paid to the psychological and behavioral aspects of diabetes. Research in this area aims to reduce the burden of diabetes and improve the overall quality of life for individuals with T1D.

Despite these advancements, there remain gaps in our understanding and management of T1D. This Special Issue aims to raise awareness about T1D, disseminate information on recent advancements, and identify future directions for research and development.

We invite researchers and clinicians to submit their original research articles, reviews, and case studies that address these topics. Your contributions will be invaluable in shaping the future of T1D management and improving the lives of those affected by this condition.

Dr. Marina Basina
Prof. Dr. Daniela Foti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Endocrines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• type 1 diabetes risk
• diabetes technology
• continuous glucose monitoring
• insulin
• quality of life with type 1 diabetes